128O PDL1/CD274 gain/amplification as a predictive marker of checkpoint blockade inhibitor efficacy in metastatic breast cancer: Exploratory analysis of the SAFIR02-IMMUNO randomized phase II trial
Titel:
128O PDL1/CD274 gain/amplification as a predictive marker of checkpoint blockade inhibitor efficacy in metastatic breast cancer: Exploratory analysis of the SAFIR02-IMMUNO randomized phase II trial
Auteur:
Bachelot, T. Filleron, T. Dalenc, F. Bieche, I. Gaberis, I. Rouleau, E. Tran-Dien, A. Adam, J. Lusque, A. Jimenez, M. Jacquet, A. André, F.